75-60-5 | Sigma-Aldrich

PLA & PLGA Polymer Portfolio for Peptide & Small Molecule Formulation

10-25 EXPANSORB® DLG 75-4E 5.43139 PLGA 75/25 ESTER 0.30-0.50 25-60 EXPANSORB® DLG 75-7E 5.43140 PLGA 75/25 ESTER 0.66-0.80 80-115 EXPANSORB® DLG 75-9E 5.43141 PLGA 75/25 ESTER 0.75-1.00 100

Poster: Virus clearance using Eshmuno HCX

Wash Wash Elution Elution 80-100 60-80 40-60 20-40 0-2080-100 60-80 40-60 20-40 0-20 80-100 60-80 40-60 20-40 0-20 80-100 60-80 40-60 20-40 0-20 7.06.56.05.55.04.5 pH 7.06.56.05.55.04.5

PureFlex™ Plus Single-use Process Container Film

extracted at room temperature.1 0 15 30 45 60 75 1 7 30 60 90 120 0 15 30 45

Superior Performance of the ProteoPrep BlueAlbumin Depletion Kitfor 2D Electrophoresis

Centrifuge 5 sec Equilibration (2x) (400 µl Equilibration Buffer) Centrifuge 30 sec Add serum (25–100 µl) Incubate 5 min, Centrifuge 60 sec Reapply serum (25–100 µl) Incubate 5 min, Centrifuge

In Vitro Evaluation of Novel Silica Materials to Enhance the Dissolution Rate of Fenofibrate and Itraconazole

dissolved in about 90 minutes. 5 10 15 20 25 30 35 2 Theta Fenofibrate (crystalline) Drug-loaded silica (starting point) Drug-loaded silica (26 week) 65 70 75 80 85 90 95 Temperature (°C)

Viscosity-Reducing Excipients for Protein Formulation

M TM P 75 m M Om + 7 5 m M BS Ac id 75 m M Om + 7 5 m M Py r-H CI 75 m

Stability study of orally disintegrating tablets (ODT)

ODT Product A Product B Product C Product D Product E 5 Figure 3: Colour measurement of tablets stored at 40 °C/75% r.H. over 26 weeks (n = 5) Figure 4: Colour of ‟Product A” tablets

PureFlex™ and PureFlex™ Plus White Paper

butanone(TIC) 75-97-8 31 2-pentanone 107-87-9 17 1N HCl no acetone 67-64-1 22 Acetaldehyde (TIC) 75-7-0 60 Tert-butyl alcohol 75-65-0 18 1N HCl yes acetone 67-64-1 50 tert-butyl alcohol 75-65-0 98 Acetaldehyde

6.0 90 10 7.0 75 25 20.0 65 35 30.0 25 75120 180 240 ns it y (m V) A Im pu rit y B 40.0 25 75

Amicon® Stirred Cell Manifold

100 75 60 50 40 30 20 ml 250 50 100 150 200 200 175 150 125 100 75 60 50 40 30 20 ml 250 50 100 150 200 200

SMC®Plate Washer Evaluation Kit

2 3 4 5 6 7 8 9 10 11 12 Row Mean SD CV A 68 65 86 57 71 79 61 79 59 69 59 82 70 10 14 B 79 55 63 62 60 60

Seed Train Intensification Using High Cell Density Cryopreservation and Specially-designed Expansion Medium

5 0 75 61 2 3 4 V C D [ 10 6 V C /m L] days CHO-DG44 Expansion in Expansion Medium Expansion in ExCEll® Advanced HD Perfusion Medium 0 25 20

NovAseptic®Mixer, Drive Unit, GMP

Current (A) 60 Hz 230 VAC 460 VAC Frame GMP50 0.5 1.75 0.75 56C GMP100 0.5 1.75 0.75 56C GMP500 0.5 1.75 0.75 56C GMP1000 1 2.8 1.4 56C GMP2000 1.5 4 2 145TC GMP5000 2 5 2.5 145TC GMP20000 5 12.2 6.1 184C

Casting Equilibrating and Seeding the 3D Petri Dish

µl 12-60TR Troughs 60 4 x 15 500 µl 190 µl 12-36TO Toroids 36 6 x 6 500 µl 190 µl 24-96 Small spheroids 96 8 x 12 330 µl 75 µl 24-35 Larger

Product Information Sheet - P5380

remaining after 60 minutes • At 55 °C: ≈ 90% after 60 minutes • At 60 °C: ≈ 80% after 60 minutes • At 65 °C: ≈ 75% after 10 minutes, ≈ 50%

User Guide - 6015

100 75 60 50 40 30 20 ml 250 50 100 150 200 200 175 150 125 100 75 60 50 40 30 20 ml 250 50 100 150 200 200

Spec sheet: NovAseptic® Mixer Drive Unit GMP

194 125 75 GMP20000 GM200/4A21-6465 456 170 194 218 75 GMP20000 GM200/4B01-6465 456 170 194 125 75 GMP20000 GM200/4B21-6465 456 170 194 218 75 GMP20000 GM300/4A01-6465 456 170 194 125 75 GMP30000

The Effective Use of Protein Kinase Inhibitors

94 103 69 109 20 105 86 90 3 3 96 89 71 93 76 94 96 7 2 18 22 5 75 68 84 54 20 94 97 73 75 15 6 62 116 102

Chromatography Purification Guide

Strong 75-95 60 1-9 + + +++ Fractogel® EMD COO- (M) resin (Item #1.16886) Weak 48-60 60 < 250

Addressing Handling Challenges of Chemicals by Dry Granulation

the respective bulk material before and after storage at ambient (25 °C / 60 % rH) and accelerated conditions (40 °C / 75 % rH). At specified time points the bottles were inverted and the material was

A comparative study of hydrophobic and hydrophilic lubricants for optimal combination of galenical and dissolution properties

performace of itraconazole 1000 mL SGFsp pH 1.2; 75 rpm Time [min] 5 1 2 3 4 0 0 15 30 45 60 75 90 105 120 Pure itraconazole Tablets with 5% Poloxamer 188

Eshmuno® CPX Resin Data Sheet

125 125 100 100 100 100 100 75 75 75 75 50 50 50 50 50 25 25 25 25 25 0

NovAseptic®Mixer, Drive Unit, GMP

195 125 75 GMP20000 GM200/4A21-6465 456 169 195 220 75 GMP20000 GM200/4B01-6465 456 169 195 125 75 GMP20000 GM200/4B21-6465 456 169 195 220 75 GMP20000 GM300/4A01-6465 456 169 195 125 75 GMP30000

Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion and Polyvinyl Alcohol

20 15 10 5 0 D ru g lo ad [ % ] 30 25 20 15 10 5 0 D ru g lo ad

Polygard®CT Filters

Pore Size 01=1.0μm 05=5.0μm 10=10.0μm 25=25.0μm 50=50.0μm 75=75.0μm 99 =100.0μm C5=150.0μm Cartridge Code 0=Code 0 (2-222) O-Ring 5=Code 5 (2-222) O-Ring with Spear 7=Code 7 (2-226) O-Ring with Spear

Data Sheet - T3068

generation chromogenic substrate reaction solution (5 mM) 2. Incubate at 37 °C. 3. Add 60 µl of Innovin (supplied by Siemans) in 250 mM CaCl2 or 60 µl of Dapttin (available from Technoclone) in

Excipient combinations to manage protein viscosity for highly concentrated formulations

is reduced150 0 50 100 V is co si ty [ m P a s] 75 mM 150 mM E1 B en ch m ar k E4 E 5 co nt ro l 150 mg/mL

Scalability of the Viresolve®Pro Solution using the Micro 40 Scaling Tool

20 40 60 80 100 120 140 0 5 10 15 20 25 30 Th ro ug hp ut (L /m 2 ) Time (min) Micro 40 1 Micro

Single-pass tangential flow filtration

20% 30% 40% 50% 60% 70% 80% 90% 18-20 g/L 2-section 75 g/L 2-section 18-20 g/L 1-section 75 g/L 1-section 18-20 g/L 3-section 75 g/L 3-section

The Effective Use of Protein Kinase Inhibitors

94 103 69 109 20 105 86 90 3 3 96 89 71 93 76 94 96 7 2 18 22 5 75 68 84 54 20 94 97 73 75 15 6 62 116 102